top of page


Merck licenses SciBrunch KRAS G12D inhibitor in deal worth up to $2.13bn
Merck has secured exclusive worldwide rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor SPR2015 in an oncology licensing transaction worth up to $2.13 billion.

nuaxia
Sep 292 min read


SK Biopharmaceuticals licenses Parkinson's candidate 1ST-104 in deal worth up to $314.8m
SK Biopharmaceuticals has secured exclusive global rights to 1ST Biotherapeutics' preclinical Parkinson's disease candidate 1ST-104 in a deal worth up to $314.8 million.

nuaxia
Sep 242 min read
bottom of page